Citizens Financial Group Inc. RI Has $91.27 Million Stock Position in Eli Lilly and Company $LLY

Citizens Financial Group Inc. RI increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,092 shares of the company's stock after purchasing an additional 1,114 shares during the quarter. Eli Lilly and Company makes up 1.1% of Citizens Financial Group Inc. RI's investment portfolio, making the stock its 17th largest holding. Citizens Financial Group Inc. RI's holdings in Eli Lilly and Company were worth $91,266,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of LLY. Tortoise Investment Management LLC lifted its stake in Eli Lilly and Company by 6.7% during the second quarter. Tortoise Investment Management LLC now owns 1,314 shares of the company's stock valued at $1,576,000 after buying an additional 82 shares in the last quarter. Banco BTG Pactual S.A. purchased a new position in shares of Eli Lilly and Company in the second quarter worth approximately $248,000. UNIVEST FINANCIAL Corp increased its position in shares of Eli Lilly and Company by 4.2% in the second quarter. UNIVEST FINANCIAL Corp now owns 33,820 shares of the company's stock worth $40,565,000 after acquiring an additional 1,375 shares in the last quarter. Auxano Advisors LLC raised its holdings in shares of Eli Lilly and Company by 2.4% during the second quarter. Auxano Advisors LLC now owns 2,118 shares of the company's stock valued at $2,540,000 after acquiring an additional 50 shares during the period. Finally, Quent Capital LLC raised its holdings in shares of Eli Lilly and Company by 7.9% during the second quarter. Quent Capital LLC now owns 5,433 shares of the company's stock valued at $6,516,000 after acquiring an additional 400 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,257.26 on Monday. The company has a market capitalization of $1.18 trillion, a PE ratio of 42.19, a PEG ratio of 1.48 and a beta of 0.51. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company's 50 day moving average price is $1,180.14 and its 200 day moving average price is $1,059.93. Eli Lilly and Company has a 52 week low of $694.23 and a 52 week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts expect that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 23.22%.

Insider Activity at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company's stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will collaborate with Boston-based Chai Discovery on an RNA vaccine platform. The partnership could expand Lilly’s technology and early-stage pipeline, though the financial impact is likely to be longer term. Lilly to work with Boston-based firm to develop RNA vaccine platform
• Positive Sentiment: Recent coverage continues to highlight Lilly’s momentum in obesity treatment, with its products reportedly outpacing Novo Nordisk’s offerings. This reinforces expectations for sustained demand and supports LLY’s growth narrative. Eli Lilly's obesity treatments outpace Novo Nordisk
• Positive Sentiment: Analyst-focused coverage identifies Eli Lilly as a leading candidate for significant earnings growth and a potential buy point as the broader market rebounds. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
• Neutral Sentiment: Lilly completed or advanced several clinical studies, including trials involving hidradenitis suppurativa, lebrikizumab, LY4178256 and eloralintide. The updates broaden the pipeline, but no decisive efficacy or regulatory results were provided. Lilly clinical-trial updates
• Neutral Sentiment: Discussion of a possible stock split reflects the sharp rise in LLY’s share price, but a split would not change the company’s fundamental value or earnings outlook. Stock Split Watch: Is Eli Lilly Stock Next?
• Negative Sentiment: Lilly continues to face competition from Novo Nordisk in the emerging oral GLP-1 market. The race creates substantial growth potential but also raises execution and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a "hold" rating in a research report on Monday, June 22nd. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research note on Friday, August 7th. Morgan Stanley restated an "overweight" rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 6th. Finally, Truist Financial raised their target price on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,292.18.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source